In addition to direct drug delivery, nanoparticles package small interfering RNAs (siRNAs) targeting PD-1 and T-cell immunoglobulin mucin 3 (TIM-3) to restore T cell immunity and sensitize the response of cancer cells to T cell killing (43, 44). The gene discussed is HAVCR2; the disease is cancer.